- Home
- HPP vs CELC Comparison
HPP vs CELC Comparison
Compare HPP & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- CELC
- Stock Information
- Founded
- HPP 1997
- CELC 2011
- Country
- HPP United States
- CELC United States
- Employees
- HPP N/A
- CELC N/A
- Industry
- HPP Real Estate
- CELC Medical Specialities
- Sector
- HPP Finance
- CELC Health Care
- Exchange
- HPP Nasdaq
- CELC Nasdaq
- Market Cap
- HPP 319.5M
- CELC 327.3M
- IPO Year
- HPP 2010
- CELC 2017
- Fundamental
- Price
- HPP $2.27
- CELC $10.15
- Analyst Decision
- HPP Hold
- CELC Strong Buy
- Analyst Count
- HPP 10
- CELC 6
- Target Price
- HPP $3.19
- CELC $30.17
- AVG Volume (30 Days)
- HPP 2.4M
- CELC 190.9K
- Earning Date
- HPP 05-07-2025
- CELC 05-14-2025
- Dividend Yield
- HPP 2.18%
- CELC N/A
- EPS Growth
- HPP N/A
- CELC N/A
- EPS
- HPP N/A
- CELC N/A
- Revenue
- HPP $818,699,000.00
- CELC N/A
- Revenue This Year
- HPP $0.13
- CELC N/A
- Revenue Next Year
- HPP $5.00
- CELC N/A
- P/E Ratio
- HPP N/A
- CELC N/A
- Revenue Growth
- HPP N/A
- CELC N/A
- 52 Week Low
- HPP $2.00
- CELC $7.58
- 52 Week High
- HPP $6.29
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- HPP 45.45
- CELC 46.58
- Support Level
- HPP $2.09
- CELC $9.64
- Resistance Level
- HPP $2.38
- CELC $10.80
- Average True Range (ATR)
- HPP 0.15
- CELC 0.66
- MACD
- HPP 0.04
- CELC -0.06
- Stochastic Oscillator
- HPP 68.42
- CELC 25.25
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.